CTKB - CIK 0001831915
The table below shows Cytek Biosciences, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$4.69M | $25.38M | $5.28M | -$12.23M | $4.63M | $15.16M |
| Capital expenditure | $4.08M | $3.52M | $4.65M | $9.75M | $4.36M | $1.55M |
| Investing cash flow | $10.12M | -$82.97M | -$93.89M | -$55.91M | -$20.99M | -$1.55M |
| Dividends paid | - | - | - | - | - |
Cytek Biosciences, Inc. reported operating cash flow of -$4.69M for fiscal year 2025. That is down 118.5% from $25.38M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from $15.16M (FY 2020) to -$4.69M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | $15.07M | $21.61M | $44.15M | $0.00 | $0.00 | - |
| Financing cash flow | -$13.43M | -$15.82M | -$41.81M | $5.51M | $213.56M | $122.61M |